In the Media

Edison Talks: Interview with Eric Adams, CEO of InMed Pharmaceuticals
In the first episode of Edison Talks, Maxim Jacobs, Edison’s director of research for North America, discusses InMed’s biosynthesis platform and its pipeline of cannabinoids...
Executive interview – InMed Pharmaceuticals
In this interview, Eric Adams, chief executive officer of InMed Pharmaceuticals provides an overview of InMed’s differentiated biosynthesis platform and its therapeutic pipeline of cannabinoids....
Source: Edison Group
Producing Cannabinoids Without the Plant!
A biosynthesis platform technology Cannabinoids are closely related compounds that are the active constituents of the cannabis plant. While there are over 100 different cannabinoids, the...
Source: BTV
Reimagining Medicine? Novartis Wraps Pharma’s First Big Global Pot Deal
In a watershed moment for medical cannabis advocates in the United States, Swiss giant Novartis’ $NVS Sandoz AG unit has tied up with Canadian medical...
Source: Endpoints News
The Promise of Cannabinoids to Treat Pain
The focus of treating pain over the last decade has led to the emergence of a number of opioid drugs. Since their introduction, this method...
Source: Money Inc
Looking Through the Telescope Onto the Horizon: InMed Pharmaceuticals
Nearly every week, there is another cannabis-themed headline such as “New Study Says 97% of Elderly Patients Say Cannabis Makes Them Feel Better, Decrease Prescription...
Source: Terpenes and Testing Magazine